Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

David Goel Biography and Net Worth

Director of Adaptive Biotechnologies

David E. Goel serves as Independent Director of the Company. Mr. Goel is Co-Founder and sole Managing General Partner of Matrix Capital Management Company, LP, an investment fund focused on technology and life sciences. Mr. Goel serves as a director on several private company boards and previously served as a director of Popular, Inc., a public financial services company. He is a member of the Board of Trustees of The Winsor School and the Museum of Fine Arts in Boston, Massachusetts. Mr. Goel holds a BA, magna cum laude, from Harvard University.

What is David E. Goel's net worth?: The estimated net worth of David E. Goel is at least $10,897.44 as of March 8th, 2021. Mr. Goel owns 3,504 shares of Adaptive Biotechnologies stock worth more than $10,897 as of May 7th. This net worth evaluation does not reflect any other investments that Mr. Goel may own. Learn More about David E. Goel's net worth.
How do I contact David E. Goel?: The corporate mailing address for Mr. Goel and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on David E. Goel's contact information.
Has David E. Goel been buying or selling shares of Adaptive Biotechnologies?: David E. Goel has not been actively trading shares of Adaptive Biotechnologies during the past quarter. Most recently, David E. Goel sold 56,000 shares of the business's stock in a transaction on Wednesday, March 10th. The shares were sold at an average price of $41.96, for a transaction totalling $2,349,760.00. Learn More on David E. Goel's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 373,179 shares worth more than $2,435,243.14. The most recent insider tranaction occured on March, 5th when insider Kyle Piskel sold 7,727 shares worth more than $26,503.61. Insiders at Adaptive Biotechnologies own 5.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 3/5/2024.

David E. Goel Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2021	Sell	56,000	$41.96	$2,349,760.00
3/8/2021	Sell	500,000	$39.50	$19,750,000.00	3,504
7/20/2020	Sell	2,000,000	$40.00	$80,000,000.00

David E. Goel Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $3.11

$3.10

$3.28

50 Day Range

MA: $3.08

$2.34

$4.15

2 Week Range

Now: $3.11

$2.28

$9.08

Volume

1,110,511 shs

Average Volume

1,602,749 shs

Market Capitalization

$458.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27